BERKELEY HEIGHTS, N.J., Oct. 18 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that new clinical and preclinical data on Genasense(R) (oblimersen sodium) Injection, its lead anticancer compound, will be presented at the "Molecular Targets and Therapeutics" conference that will take place from October 22-26, 2007 in San Francisco, CA. The "Targets" meeting is jointly sponsored by the U.S. National Cancer Institute (NCI), the American Association for Cancer Research (AACR), and the European Organization for the Research and Treatment of Cancer (EORTC).
Titles and dates of the presentations include the following:
#A180: Bcl-2 antisense oligodeoxynucleotides and GSH depletion-induced sensitization to chemotherapy lead to complete regression of A375 melanoma xenografts. Presenter: S. Menal, University of Valencia. October 23, 2007.
#A166: Phase 1 pharmacokinetic and pharmacodynamic study of oblimersen (Genasense) administered as a weekly 2-hr intravenous infusion. Presenter: A. Tolcher, South Texas Accelerated Research Therapeutics, San Antonio, TX. October 23, 2007.
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.
Genta Incorporated is a biopharmaceutical company with a diversified
product portfolio that is focused on delivering innovative products for the
treatment of patients with
|SOURCE Genta Incorporated|
Copyright©2007 PR Newswire.
All rights reserved